Skip to main content

Ayala Pharmaceuticals, Inc.

ADXSDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001100397

Ayala Pharmaceuticals, Inc. was delisted in 2025; its insiders filed their last Form 4 on Mar 6, 2024; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ayala Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ayala Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ayala Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Israel Biotech Fund I, L.P.Director, 10% Owner25,130,903IndirectMar 6, 20240
Israel Biotech Fund II, L.P.Director, 10% Owner25,130,903IndirectMar 6, 20240
I.B.F. Management Ltd.Director, 10% Owner25,130,903IndirectMar 6, 20240
Israel Biotech Fund GP Partners, L.P.Director, 10% Owner25,130,903IndirectMar 6, 20240
Israel Biotech Fund GP Partners II, L.P.Director, 10% Owner25,130,903IndirectMar 6, 20240
aMoon Growth Fund Limited Partnership10% Owner560,602Oct 23, 20230
Goldberg Murray ADirector–Jan 23, 20230
Sidransky DavidDirector46IndirectJan 23, 20230
Spiegel Robert J.Director–Jan 23, 20230
Bisker-Leib VeredDirector–Jan 23, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 21, 2023 (view filing)9:04 AM ETNov 174 daysIsrael Biotech Fund I, L.P. and 4 others10% OwnerPPurchase+43.8M–––27.6M afterDerivative10 lots
Oct 31, 2023 (view filing)7:08 AM ETOct 1813 daysLateIsrael Biotech Fund I, L.P. and 4 others10% OwnerPPurchaseCommon Stock, par value $0.001 per share+1.32M$0.00$0New position1.09M after2 lots
Sep 29, 2023 (view filing)6:13 AM ETSep 128 daysIsrael Biotech Fund I, L.P. and 4 others10% OwnerPPurchase+1.74M–––434.8K afterAmendedDerivative2 lotsPrice outlierDuplicate filing
Sep 11, 2023 (view filing)12:44 PM ETSep 110 daysLateIsrael Biotech Fund I, L.P. and 1 other10% OwnerPPurchase+1.74M–––434.8K afterDerivative2 lotsPrice outlier